1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Orexo AB (publ)

Orexo AB (publ)

ORXOF
Orexo AB (publ)US flagOther OTC
1.77
USD
- -
- -
62.17MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
14.3
17.46
18.74
20.47
18.64
22.66
24.4
19.29
16.46
18.17
18.56
0.86
0.75
0.34
Basic EPS, GAAP
-5.16
-1.73
-6.09
0.84
0.67
3.99
6.33
-2.45
-6.51
-5.17
-3.73
-5.89
18.46
14.02
Free Cash Flow per Basic Share
-12.35
-14.92
-3.28
4.49
4.2
6.9
7.37
-5.03
-8.21
-5.25
-3.32
-9.6
-5.64
-4.34
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-43.7
-41.57
-45.44
-44.62
-43.87
-39.85
-33.45
-36.12
-42.72
-47.85
-51.49
-57.26
-38.9
- -
Tangible Book Value per Share
-1.11
6.39
3.32
4.99
6.02
10.77
17.11
8.89
2.94
-0.68
-3.32
-4.44
14.16
7.74
Basic Weighted Avg Shares
30
33
34
34
35
35
35
34
34
34
34
34
35
35
Sales/Revenue/Turnover
429
570
646
706
644
783
845
664
565
624
639
30
26
12
Operating Margin (%)
-32.53
-4.38
-27.95
-3.47
3.01
9.87
26.12
-5.68
-39.81
-34.31
-16.97
-1,457.91
-1,310
-2,383.9
Depreciation Expense
51
13
81
25
21
21
41
39
53
69
77
165
67
50
Net Income, GAAP
-155
-57
-210
29
23
138
219
-84
-224
-178
-128
-203
639
490
Effective Tax Rate (%)
- -
- -
- -
18.26
21.89
- -
3.86
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-36.09
-9.92
-32.5
4.11
3.6
17.61
25.94
-12.72
-39.56
-28.45
-20.08
-683.5
2,458.85
4,156.78
Working Capital
47
678
571
516
478
576
760
230
485
350
196
215
850
150
LT Debt
104
494
494
398
319
321
323
47
530
519
453
466
484
3
Total Equity
161
468
270
310
329
476
706
558
350
194
59
-126
491
271
Return on Invested Capital (%)
- -
- -
- -
-2.71
2.22
- -
22.88
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-4.3
-3.45
- -
-25.43
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
8
4
7
LT Borrowings
483
- -
- -
LT Finance Leases
1
3
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
35
35
35
Market Capitalization
1,034
759
712

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,165
476
380
Cash, Cash Equivalents & STI
912
386
277
Accounts Receivable, Net
185
17
28
Inventories
- -
- -
- -
Total Current Liabilities
315
235
230
Payables & Accruals
- -
- -
- -
ST Debt
8
4
7
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-86.14%
-190.89%
-488.44%
Free Cash Flow
-20.02%
27.86%
-41%
Net Income, GAAP
4.07%
-48.04%
-414.93%
Sales/Revenue/Turnover
-10.13%
-21.97%
-12.46%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
139
154
136
8
30
2025
13
5
- -
3
26
2026
5
4
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.26
-1.04
-1.21
-3.37
-5.89
2025
-0.46
-1.15
- -
20.88
18.46
2026
-3.81
-2.86
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Nikolaj Sorensen
Full Time Employees
65
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
P.O. Box 303 Uppsala UP Sweden 751 05
IPO Date
Apr 11, 2013
Website
orexo.com
Similar Companies
New Leaf Ventures Inc (NLV.CN)
Embecta Corp. (EMBCV)
Saudi Pharmaceutical Industries and Medical Appliances Corporation (2070.SR)
BioNxt Solutions Inc. (BNXT.CN)
Bausch Health Companies Inc. (BHC)
Shanghai Haoyuan Chemexpress Co., Ltd. (688131.SS)
Business
Orexo AB (publ) Orexo AB (publ) is a commercial-stage specialty pharmaceutical company that develops and commercializes improved pharmaceuticals and digital therapies addressing unmet needs in opioid use disorder, substance abuse, and mental health using proprietary drug delivery technologies including the AmorphOX powder-based platform; core products comprise Zubsolv (buprenorphine/naloxone sublingual tablet) and Izipry (high-dose naloxone intranasal powder) for opioid use disorder treatment and overdose reversal in the US, alongside digital mental health programs, with partner-led commercialization of other therapies globally. Founded in 1995 and headquartered in Uppsala, Sweden, the company maintains an international footprint with operations in the United States via its wholly owned subsidiary Orexo US, Inc. in Morristown, New Jersey, and collaborations worldwide targeting patients, caregivers, healthcare professionals, and first responders. In September 2025, Orexo US secured USD 8 million initial funding from the US Biomedical Advanced Research and Development Authority (BARDA) under a potential USD 50.9 million contract to advance OX390, an investigational intranasal AmorphOX-based rescue medication for adulterated opioid overdose-induced respiratory depression.

Company News

APIChatGPT

  • seekingalpha.com

    Orexo AB (publ) (ORXOY) Q1 2026 Earnings Call Transcript